CA
NZ
UK
AU
IND
US
argenx (NASDAQ:ARGX) reported second-quarter Vyvgart net sales of $1.516 billion on 23 July, up 60% year on year and ahead of analyst consensus, and the Nasdaq-listed shares closed 8.6% higher the same day. The company is now durably profitable with $5.2 billion of liquidity, …
Arrowhead (NASDAQ:ARWR) shares closed 19% higher on 22 July 2026 after two Phase 3 studies showed its quarterly injection cut triglycerides by around 80% and reduced acute pancreatitis events in patients with severe hypertriglyceridemia. The data open a market of millions rather than thousands …
Celldex (NASDAQ:CLDX) said on 21 July 2026 that barzolvolimab failed to beat placebo on itch in a 140-patient Phase 2 trial in prurigo nodularis, and that it is abandoning the indication. Shares dropped as much as 10% after hours but closed the next session …
Vertex Pharmaceuticals agreed on 6 July 2026 to buy San Diego endocrine specialist Crinetics (NASDAQ:CRNX) for US$85.00 a share in cash, a 102% premium that sent the stock up roughly 99% the next session. For Crinetics holders the question has shifted from drug development …
Agios (NASDAQ:AGIO) said on 21 July 2026 that it will stop developing tebapivat in sickle cell disease after a Phase 2 study failed to separate convincingly from placebo, and the shares closed down 7.1%. With the same molecule already shelved in myelodysplastic syndromes two …
AtriCure, Inc. (NASDAQ:ATRC) appeared on the gainers list showing an advance of roughly 6%. The exact timing is unconfirmed, and with live quote feeds and the company's investor-relations wire not independently reachable, the exact session behind that move cannot be tied to a single …
EUDA Health Holdings Limited (NASDAQ:EUDA) surfaced on the gainers list with a move of roughly 7%. The exact timing was unconfirmed, and with live market data limited at the time of writing, the exact session and closing level behind the gain could not be …
Integra LifeSciences (NASDAQ:IART) surfaced on the gainers list at roughly +7%, but that reading is undated, and independent verification of the exact session and magnitude was not possible during this research because live quote feeds were unavailable. Readers should treat the figure as indicative …
Advanced Biomed Inc. (NASDAQ:ADVB) rose roughly 13% in an undated recent session - a modest number by this stock's standards. In the days around 20-24 July 2026, ADVB posted single-session moves reported between roughly 35% and 73%, triggering repeated volatility halts, so a 13% …
Few small-cap biotechnology stories turn as sharply as this one. On January 29, 2026, Quince Therapeutics, Inc. (NASDAQ:QNCX) disclosed that its pivotal Phase 3 NEAT trial of eDSP in ataxia-telangiectasia had missed both its primary and its key secondary endpoint, and that it would …
Please wait processing your request...